iRhythm/$IRTC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About iRhythm
iRhythm Technologies Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.
Ticker
$IRTC
Sector
Primary listing
Industry
Health Care Equipment and Supplies
Headquarters
Employees
2,000
ISIN
US4500561067
Website
iRhythm Metrics
BasicAdvanced
$4.3B
-
-$3.14
1.41
-
Price and volume
Market cap
$4.3B
Beta
1.41
52-week high
$157.13
52-week low
$55.92
Average daily volume
439K
Financial strength
Current ratio
5.712
Quick ratio
5.4
Long term debt to equity
830.049
Total debt to equity
848.672
Interest coverage (TTM)
-4.85%
Profitability
EBITDA (TTM)
-58.414
Gross margin (TTM)
69.39%
Net profit margin (TTM)
-15.89%
Operating margin (TTM)
-10.38%
Effective tax rate (TTM)
-1.23%
Revenue per employee (TTM)
$310,000
Management effectiveness
Return on assets (TTM)
-4.37%
Return on equity (TTM)
-111.13%
Valuation
Price to revenue (TTM)
6.901
Price to book
50.17
Price to tangible book (TTM)
50.68
Price to free cash flow (TTM)
-4,039.015
Free cash flow yield (TTM)
-0.02%
Free cash flow per share (TTM)
-3.37%
Growth
Revenue change (TTM)
20.54%
Earnings per share change (TTM)
-25.81%
3-year revenue growth (CAGR)
21.97%
3-year earnings per share growth (CAGR)
-9.38%
What the Analysts think about iRhythm
Analyst ratings (Buy, Hold, Sell) for iRhythm stock.
Bulls say / Bears say
Wolfe Research upgraded iRhythm Technologies to 'Outperform' with a price target of $115, citing a 'sensible entry valuation' and anticipated resolution of key overhangs within the next 12 months. (Investing.com)
iRhythm's exclusive license agreement with BioIntelliSense is expected to enhance its ambulatory cardiac monitoring capabilities, potentially boosting revenue growth in the segment. (Nasdaq)
The company reported a significant 18.4% year-over-year increase in revenue for Q1 2024, reaching $131.9 million, driven by strategic initiatives and new partnerships. (Investing.com)
A class action lawsuit alleges iRhythm failed to comply with FDA marketing regulations and reporting requirements, potentially leading to financial and reputational damage. (Business Wire)
The company reported a net loss of $46.2 million in Q3 2024, primarily due to a $32.1 million charge related to the BioIntelliSense license agreement, raising concerns about profitability. (StockTitan)
iRhythm received a warning letter from the FDA detailing serious issues with the Zio AT device, including its use in high-risk patients despite approval only for non-critical cases. (Business Wire)
Data summarised monthly by Lightyear AI. Last updated on 9 Jul 2025.
iRhythm Financial Performance
Revenues and expenses
iRhythm Earnings Performance
Company profitability
iRhythm News
AllArticlesVideos
iRhythm Technologies to Report Second Quarter 2025 Financial Results on July 31, 2025
GlobeNewsWire·4 days ago
iRhythm Technologies Announces Board Member Retirements and New Director Appointments
GlobeNewsWire·2 weeks ago
IRHYTHM INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of iRhythm Technologies, Inc. - IRTC
Business Wire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for iRhythm stock?
iRhythm (IRTC) has a market cap of $4.3B as of July 21, 2025.
What is the P/E ratio for iRhythm stock?
The price to earnings (P/E) ratio for iRhythm (IRTC) stock is 0 as of July 21, 2025.
Does iRhythm stock pay dividends?
No, iRhythm (IRTC) stock does not pay dividends to its shareholders as of July 21, 2025.
When is the next iRhythm dividend payment date?
iRhythm (IRTC) stock does not pay dividends to its shareholders.
What is the beta indicator for iRhythm?
iRhythm (IRTC) has a beta rating of 1.41. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.